Clinical studies on PD-L1 as a predictive and prognostic biomarker in EGFR-mutant NSCLC treated with EGFR-TKIs have shown mixed results [12], emphasizing the need for further research. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.